Pharmaceuticals Inc. (DFFN) (“Diffusion” or “Company”)
Gainer, Ph.D. Dr. Gainer will continue to serve as a consultant to the company and as a member of the board of directors. Recognizing the advancement of DSC technology in the clinic, the company has begun looking for a chief medical officer to replace the former chief scientific officer.If you want to know more stock news like Nyse 111, you can check at https://www.webull.com/quote/nyse-lll .
Professor Gainer is the inventor of the trans-dipole carotenoid family molecules, from which the company’s leading compound Trans sodium cruciate or TSC is derived. He co-founded Diffusion Pharmaceuticals in 2001 with David Galerkis, president and CEO of the company, serving on the board of directors. He was appointed Chief Scientific Officer in 2005 after retiring as Professor Emeritus in the Department of Chemical Engineering at the University of Virginia, where he has served as a faculty member since 1966.
“On behalf of everyone at Diffusion Pharmaceuticals, we would like to congratulate Professor Gainer on the best he can with the pension he deserves,” said Mr. Greene.
About Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. An innovative biotechnology company that is developing a new treatment that improves the body’s ability to bring oxygen to areas that need it most, and provides new hope for treating life-threatening medical conditions.
The evolution of research has led to the focus of diffusion today: fueling life by taking on some of the most complex and difficult to treat drugs, including stroke and GBM brain cancer. In each of these diseases, hypoxia – the lack of oxygen in the body’s essential tissues – has proven to be a significant barrier to medical providers and is the target of a new mechanism of DSC.
In July 2019, the company reported favorable safety data for its Phase 3 INTACT program in a 19-patient dose-escalation run-in study of DSC targeting to an inoperable GBM target. Further findings from a dose-escalation run-in study published in December 2019 also showed signs of improved survival and patient performance. Diffusion’s on-ambulance PHAST-TSC test for severe stroke has begun patient admission. Also, DSC may be used as a treatment for other conditions in which hypoxia plays an important role, such as myocardial infarction, COPD, respiratory diseases, peripheral artery disease, and neurodegenerative conditions such as Alzheimer’s and Parkinson’s disease.
Furthermore, RES-529, the company’s PI3K / AKT / mTOR pathway inhibitor that separates the mTORC1 and mTORC2 complexes, is in preclinical testing for GBM.
Any statements made in this press release deal with non-historical information, which are forward-looking statements under the 1995 Private Securities Litigation Act. This news is one of the stock news, you can gain more like Nasdaq sedg at https://www.webull.com/quote/nasdaq-sedg .